Thanks, Anthony. I added the following message to the many that CNBC will receive from PFE threaders today:
Dear Sirs,
As a dedicated CNBC watcher, I am disturbed about the focus of your coverage of Pfizer, Inc. (PFE). This company is a clear leader in the pharmaceutical industry, and has multiple offerings that appear regularly in the list of top name brand prescriptions issued (Zithromax, Zoloft, Norvasc, as well as the now famous Viagra). But your recent reporting seems focused on sensational and speculative aspects related to the actuarially small number of deaths of Viagra users while ignoring solid news that will drive the market value of Pfizer. I feel that you will be doing Pfizer, its shareholders, and the financial community a disservice by continuing this one dimensional coverage, and would urge you review your editorial policy. Hopefully CNBC will continue to present objective financial information, and not try to compete with the tabloid journalism "news" shows.
Very truly yours,
|
